Phase 2 N=77 Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Chronic Hepatitis C
Primary: Number of Participants With Grade 3 and 4 Adverse Events — 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=104 Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
Pancreatic Cancer
Primary: Evans Grade Histopathologic Response — 10; 7; 17; 12 number of participants
Phase 2 N=280 Effect of KYG0395 on Primary Dysmenorrhea
Primary Dysmenorrhea
Primary: The Change From Baseline to the End of Treatment Period in Maximum Dysmenorrheic Pain VAS Score — -19.8; -18.0; -14.4 units on a scale — p=>0.05
Phase 2 N=70 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Lung Cancer
Primary: Proportion of Patients With Target Adverse Events for the Step 2 Treatment — 0.03 proportion of participants
Phase 2 N=46 Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Primary: Change in Soluble Vascular Cell Adhesion Molecule-1 (sVCAM) — -3.2; 4.17 ng/mL
Phase 2 N=16 Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
Crohn's Disease
Primary: Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During Study Treatment (up to 303 Weeks) — 2; 6; 2 Participants
Phase 2 N=31 ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
Rheumatoid Arthritis
Primary: Disease Activity Score 28-CRP (DAS28-CRP) at Week 4 — 5.40; 5.05 Scores on scale
Phase 2 N=8 Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
Psychotic Disorders · Schizophrenia · Schizoaffective Disorder
Primary: Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score — 31.96; 0.96 score
Phase 2 N=23 Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
Myeloma · Transplant-eligible Patients
Primary: Number of Participants With Adverse Events in All Subjects — 11 Participants
Phase 2 N=68 Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route
C. Difficile
Primary: Safety as Assessed by Number of Participants With Any Adverse Events (AE)s — 4; 4 Participants — p=0.8958
Phase 2 N=252 Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
Postmenopausal Osteoporosis (PMO)
Primary: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine — 0.9; 8.4; 13.3; 16.9 percent change — p=< 0.0001
Phase 2 N=80 A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
Breast Neoplasms
Primary: 1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) — 23.29…
Phase 2 N=67 Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52 — -0.16…
Phase 2 N=58 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
Brain Tumors · Spinal Cord Tumors
Primary: Time to Progression — 7.8 Months
Phase 2 N=20 Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342
Tuberculosis
Primary: Concentration of Specific Interferon Gamma (IFN-γ) Antibodies Secreted in Serum Samples — 6279.7 fg/mL